Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Audra Marcum

Nurse Practitioner, Acute Care Lexington, KY Nurse Practitioner

NPI 1497703987 CMS profile 10445986

2400 Harrodsburg Rd, Lexington, KY 40503

Open in the dashboard

General payments

$13,685

772 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Audra Marcum of Lexington, KY is reported in the CMS Open Payments database as having received $13,685 across 772 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,154 167
2024 General $2,733 145
2023 General $3,276 165
2022 General $2,535 154
2021 General $1,985 141

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Audra Marcum
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Audra Marcum were reported at $3,154. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Audra Marcum Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,985 $123 $38–$327 $132
2022 $2,535 $130 $44–$369 $149
2023 $3,276 $144 $49–$410 $160
2024 $2,733 $146 $48–$433 $164
2025 $3,154 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $2,112 146 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $2,001 130 payments
  3. AstraZeneca Pharmaceuticals LP $998 31 payments
  4. Grifols USA, LLC $945 52 payments
  5. Genzyme Corporation $855 44 payments
  6. Regeneron Healthcare Solutions, Inc. $676 38 payments
  7. Mylan Specialty L.P. $626 39 payments
  8. Amgen Inc. $611 39 payments
  9. Insmed, Inc. $586 33 payments
  10. Genentech USA, Inc. $419 37 payments
  11. Other $3,857 183 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,540 768 payments
  2. Education $144 4 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $1,243 83 payments
  2. Prolastin-C Liquid $945 52 payments
  3. DUPIXENT Immunology $917 45 payments
  4. NUCALA $847 61 payments
  5. YUPELRI $819 48 payments
  6. OFEV $766 46 payments
  7. STIOLTO RESPIMAT $709 55 payments
  8. FASENRA $648 18 payments
  9. DUPIXENT Inflammation And Immunology $611 35 payments
  10. Arikayce $568 32 payments
  11. Other $8,189 430 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

3,204

Median for Nurse Practitioner: 389

Drug cost

$1,971,334

Median for Nurse Practitioner: $21,885

Branded share of claims

69.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 37 $487,543
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 444 $413,553
Nucala Mepolizumab Brand 56 $221,148
Dupixent Pen Dupilumab Brand 38 $141,678
Fasenra Pen Benralizumab Brand 20 $113,142
Dupixent Syringe Dupilumab Brand 26 $111,606
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 129 $108,415
Spiriva Respimat Tiotropium Bromide Brand 79 $64,732
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 89 $61,226
Breo Ellipta Fluticasone/Vilanterol Brand 99 $55,668

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$71,099

Of which drugs: $7,627

Medicare patients

394

Average age 74

Services billed

1,319

239 women, 155 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 72%
Arthritis 59%
Ischemic heart disease 52%
Diabetes 37%
Depression 36%
Heart failure 32%
Chronic kidney disease 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 21 21 $6,079
Vaccine for influenza for injection into muscle 90662 Office 19 19 $1,525

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$420 64 —
NUCALA
$251 56 —
OFEV
$219 37 —
YUPELRI
$214 — —
TRELEGY ELLIPTA
$198 444 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

772 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Acute Care in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record